Akeso
AK104 (New Site)(Akeso)은 Healthy Male Adults Participants 표적 치료제로, Healthy Male Adults Participants 영역에서 개발·상용화 중입니다. 작용기전: target due to its pivotal role in oncogenic signaling. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 61건의 관련 임상이 등록되어 있습니다. 차별점: novel radio-immunotherapeutic agent for the treatment of non-small-cell lung cancer (NSCLC) and explored its underlying thera.
Healthy Male Adults Participants
Healthy Male Adults Participants
Recruiting
Bispecific immune checkpoint inhibitors (ICIs), with their ability to
novel radio-immunotherapeutic agent for the treatment of non-small-cell lung cancer (NSCLC) and explored its underlying thera
target due to its pivotal role in oncogenic signaling
T cell activation
microtubule organizing centers (aMTOC)
PD-L1 expression
resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR mutations (EGFRm
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Akeso
AK104 (New Site)(Akeso)은 Healthy Male Adults Participants 표적 치료제로, Healthy Male Adults Participants 영역에서 개발·상용화 중입니다. 작용기전: target due to its pivotal role in oncogenic signaling. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 61건의 관련 임상이 등록되어 있습니다. 차별점: novel radio-immunotherapeutic agent for the treatment of non-small-cell lung cancer (NSCLC) and explored its underlying thera.
Healthy Male Adults Participants
Healthy Male Adults Participants
Recruiting
Bispecific immune checkpoint inhibitors (ICIs), with their ability to
novel radio-immunotherapeutic agent for the treatment of non-small-cell lung cancer (NSCLC) and explored its underlying thera
target due to its pivotal role in oncogenic signaling
T cell activation
microtubule organizing centers (aMTOC)
PD-L1 expression
resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR mutations (EGFRm
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.